Trials / Unknown
UnknownNCT01592266
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With Acute Myeloid Leucemia(AML)
F18-FLT PET/CT as a Tool for Assessment of Myeloablative Treatment in Patients With AML
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PET/CT is reliable tool in evaluation of treatment response in number cancers. F18-FLT is a precursor of DNA with high uptake in the bone marrow as a part of normal biodistribution. Highly increased uptake of this radiopharmaceutical was shown in a number of hematologic disease either in bone marrow or extramedullary. F18-FLT PET/CT can provide a tool for whole body assessment of activity in bone marrow as well as early estimation of treatment efficacy or lack of it. In addition, this noninvasive study can replace bone marrow biopsy and predict response vs. non response to therapy.
Conditions
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2013-10-01
- First posted
- 2012-05-07
- Last updated
- 2012-05-07
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01592266. Inclusion in this directory is not an endorsement.